Creatv Microtech Inc
Biotechnology, Lake Potomac Drive, Potomac, , 20854, Maryland, 11609, United States, 11-50 Employees
Who is CREATV MICROTECH INC
Creatv Microtech's mission is to dramatically reduce global cancer mortality through early detection. Our innovative blood test can detect cancer in the earliest stages, even before sympt...
Read More

-
Headquarters: 11609 Lake Potomac Drive, Potomac, Maryland, 20854, United States
-
Date Founded: 1996
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 3575
Does something look wrong? Fix it. | View contact records from CREATV MICROTECH INC
Creatv Microtech Inc Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Creatv Microtech Inc
Answer: Creatv Microtech Inc's headquarters are located at Lake Potomac Drive, Potomac, , 20854, Maryland, 11609, United States
Answer: Creatv Microtech Inc's official website is https://creatvbio.com
Answer: Creatv Microtech Inc's revenue is $1 Million to $5 Million
Answer: Creatv Microtech Inc's SIC: 3575
Answer: Creatv Microtech Inc has 11-50 employees
Answer: Creatv Microtech Inc is in Biotechnology
Answer: Creatv Microtech Inc contact info: Phone number: Website: https://creatvbio.com
Answer: Creatv Microtech's mission is to dramatically reduce global cancer mortality through early detection. Our innovative blood test can detect cancer in the earliest stages, even before symptoms. It can also confirm whether a patient is responding to treatment and surveil for early signs of recurrence after treatment has finished. Clinical application of this highly sensitive and specific test will improve cancer treatment outcomes. Cancer touches all of us. Almost 40% of Americans are currently expected to receive a diagnosis of cancer in their lifetime. Over half of these diagnoses occur after significant progression, in stages 3 and 4, making it difficult to achieve successful therapeutic outcomes. Early detection with high accuracy is needed for all major cancers. Nearly 14.5 million Americans are living with a history of cancer, many in remission under surveillance for possible recurrence. Early detection of recurrence enables faster response and improved outcomes. Our CellSieve diagnostic platform uncovered a previously unknown cell in the blood of cancer patients, the cancer associated macrophage-like cell (CAML). These cells are very large and distinctly different from normal cells and circulating tumor cells (CTCs). We found these CAMLs in patients with solid tumors, but not in healthy individuals. CAMLs are highly informative, because they contain markers of the cancer type and indicate sensitivity or resistance to particular treatments. Unlike CTCs, CAMLs are found in all stages of cancer, including stage I. Together, CAMLs and CTCs provide a unique capability for early detection of cancer, monitoring treatment, and watching for recurrence. CellSieve is currently in research use at leading cancer clinics in the US and eight foreign countries.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface

Sign in to CIENCE GO Data to uncover contact details
Free credits every month